Hundreds of Xarelto lawsuits are moving forward in the U.S. District Court for the Eastern District of Louisiana, under the guidance of the presiding court justice, Judge Eldon E. Fallon, who has scheduled a so-called “science day” for Thursday, June 11, 2015.
Over 250 lawsuits, and perhaps as many as 400, are progressing in a multi-district litigation case. An MDL was formed due to the sheer number of cases, which will still be tried separately. The MDL serves to reduce the burden on the courts, enabling authorities to oversee discovery, litigation and other proceedings for all of the cases at once.
The upcoming “science day” will serve as an opportunity to address a range of different topics, including Xarelto clinical trials, adverse symptoms associated with Xarelto, Xarelto-related blood testing procedures and the pharmacology of the blood thinner drug.
Scientists, physicians, pharmacologists and other specialists will be on hand to present information to the court, providing relevant information and insight to the court. They will also be answering questions.
The experts are required to submit copies of their June 11 presentations to the court for review no later than June 5, 2015.
The purpose of this court “science day” will be to inform the judge and other court officials about the nature of the blood thinner drug, its risks, its benefits, its composition, its recommended usage and its complications. The proceedings will be considered off the record and as such, they will not be admissible as evidence in future litigation.
Xarelto is an anticoagulant drug manufactured by Janssen Pharmaceuticals, which is a division of Bayer.
First approved for use by the U.S. Food and Drug Administration (FDA) in 2011, the blood thinner drugs is prescribed to patients who are prone to stroke and blood clots. It’s also prescribed to individuals who are suffering from a variety of medical conditions including deep vein thrombosis, atrial fibrillation, pulmonary embolism and patients who’ve undergone hip or knee replacement surgery.
Plaintiffs in the hundreds of Xarelto lawsuits allege that the drug makers over-played positive study results while downplaying dangers of the drug, such as gastrointestinal bleeding, brain hemorrhage, uncontrolled bleeding and blood clots, which incidentally, is a condition that Xarelto was reportedly designed to treat and prevent.
Critics have also come down on Janssen and Bayer for their alleged negligence in releasing a medication that does not have any known antidote.
Xarelto was reportedly presented as a safer alternative to coumadin/warfarin, which requires regular testing to ensure the drug maintains therapeutic levels. But coumadin does have an antidote – Vitamin K, which can reverse the blood thinner’s effects. No such antidote exists for Xarelto.
If you or a loved one has suffered medical complications or uncontrolled bleeding while taking Xarelto, you can still take action. Remember, the law limits the amount of time you have to take action in a personal injury case, so acting promptly is critical.